EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus

Alexandra C Willcox, Theodore A Gobillot, Caroline Kikawa, Nell E Baumgarten, Caitlin I Stoddard, Kevin Sung, Tamanash Bhattacharya, Tiia S Freeman, Joshua Marceau, Daryl Humes, Julie Overbaugh

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2507955122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Alexandra C Willcox und 10 weiteren Autor:innen. Beteiligte Einrichtung: Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109. Hauptthemen laut MEDLINE: Zika Virus, Interferon Type I, Zika Virus Infection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zika virus (ZIKV) has caused multiple human outbreaks, with more recent epidemics associated with severe outcomes in infants. Today, ZIKV is endemic to many countries and presents a persistent threat for future epidemics. The host innate immune proteins that regulate ZIKV replication are incompletely defined. We developed a CRISPR knockout screen to identify host factors that impact ZIKV replication, resulting in the finding of angiomotin-like protein 2 (AMOTL2), a protein that inhibits ZIKV by regulating the host type I interferon (IFN) response. AMOTL2 affects IFN signaling by modulating STAT1 levels and activation in response to type I IFN. Thus, AMOTL2, which has largely been studied for its role in cancer, represents an antiviral protein that interacts with the IFN signaling pathway to promote downstream expression of IFN stimulated genes, resulting in restriction of ZIKV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zika VirusInterferon Type IZika Virus InfectionHumansVirus ReplicationSignal TransductionAngiomotinsSTAT1 Transcription FactorHEK293 CellsAnimalsImmunity, InnateAntigens, Differentiation

Stichwörter der Autor:innen

AMOTL2CRISPR screenZIKVantiviral genetype I interferon

Substanzen

Interferon Type IAngiomotinsSTAT1 Transcription FactorSTAT1 protein, humanleu-13 antigenAntigens, Differentiation

Autor:innen und Institutionen

  • Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Medical Scientist Training Program, University of Washington, Seattle, WA 98195.
  • Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98195.
  • Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Willcox, A. C., Gobillot, T. A., Kikawa, C., Baumgarten, N. E., Stoddard, C. I., Sung, K., Bhattacharya, T., Freeman, T. S., Marceau, J., Humes, D., & Overbaugh, J. (2025). Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2507955122

Vancouver

Willcox AC, Gobillot TA, Kikawa C, Baumgarten NE, Stoddard CI, Sung K, et al. Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2507955122

BibTeX
@article{Willcox2025,
  author = {Willcox, Alexandra C and Gobillot, Theodore A and Kikawa, Caroline and Baumgarten, Nell E and Stoddard, Caitlin I and Sung, Kevin and Bhattacharya, Tamanash and Freeman, Tiia S and Marceau, Joshua and Humes, Daryl and Overbaugh, Julie},
  title = {Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2507955122}
}
Kostenlos starten →